GALECTO INC
(NASDAQ: GLTO)

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3, lysyl oxidase-like 2, and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

0.780

- (-%)
Range - - -   (-%)
Open 0.775
Previous Close 0.780
Bid Price 2.420
Bid Volume 9
Ask Price 2.720
Ask Volume 10
Volume 129,262
Value -
Remark
Delayed prices. Updated at 29 Mar 2024 04:00.
Data powered by
View All Events


Loading Chart...

Please login to view stock data and analysis